Substance / Medication

Lubiprostone

Overview

Active Ingredient
lubiprostone
RxNorm CUI
623033
Labeler: American Health PackagingUpdated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

[see Warnings and Precautions (5.5) ]. Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Comparative Efficacy and Safety of Lubiprostone and Osmotic Laxatives in Chronic Idiopathic Constipation: A Systematic Review and Network Meta-Analysis.
Yang Luoyao, Zong Ye, Meng Fandong et al. · J Gastroenterol Hepatol · 2025
PMID: 39660667Meta-Analysis
Association between use of lubiprostone and headache: A systematic review and meta-analysis of randomized controlled trials.
Mitsuboshi Satoru, Morizumi Makoto, Imai Shungo et al. · Br J Clin Pharmacol · 2025
PMID: 41039707Meta-Analysis
A meta-analysis of randomized controlled trials of the addition of lubiprostone to bowel preparation before colonoscopy.
Li Peng, He Xue-Qian, Dong Jie et al. · Medicine (Baltimore) · 2020
PMID: 32080109Meta-AnalysisFull text (PMC)
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.
Cryer Byron, Drossman Douglas A, Chey William D et al. · Dig Dis Sci · 2017
PMID: 28849329Meta-AnalysisFull text (PMC)
Efficacy of lubiprostone for functional constipation treatment in adolescents and children: Randomized controlled trial.
Elkaragy Engy S, Shamseya Mohammed M, Metwally Rasha H et al. · J Pediatr Gastroenterol Nutr · 2024
PMID: 38314885RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lubiprostone (substance)
SNOMED CT
421856003
UMLS CUI
C1684405
RxNorm CUI
623033
Labeler
American Health Packaging

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

1
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.